Ironwood Pharmaceuticals to Host Second Quarter 2016 Investor Update Call

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its second quarter 2016 investor update conference call and webcast at 4:30 p.m. Eastern Time on Thursday, August 4, 2016. Individuals interested in participating in the call should dial (877) 643-7155 (U.S. and Canada) or (914) 495-8552 (international) using conference ID number 49646361. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The call will be available for replay via telephone starting August 4, 2016 at approximately 7:30 p.m. Eastern Time, running through 11:59 p.m. Eastern Time on August 11, 2016. To listen to the replay, dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) using conference ID number 49646361. The archived webcast will be available on Ironwood’s website for 14 days beginning approximately one hour after the call has completed.

About Ironwood PharmaceuticalsIronwood Pharmaceuticals (NASDAQ: IRWD) is a commercial biotechnology company focused on creating medicines that make a difference for patients, building value for our fellow shareholders, and empowering our passionate team. We are advancing a pipeline of innovative medicines in areas of significant unmet need, including irritable bowel syndrome with constipation (IBS-C)/chronic idiopathic constipation (CIC), refractory gastroesophageal reflux disease, uncontrolled gout, and vascular and fibrotic diseases. We discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader in the IBS-C/CIC category, and we are applying our proven R&D and commercial capabilities to advance multiple internally-developed and externally-accessed product opportunities. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. For more information, please visitwww.ironwoodpharma.com or www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both these locations.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160721006328/en/

Ironwood Pharmaceuticals, Inc.
Media Relations
Trista Morrison, 617-374-5095
Director, Corporate Communications
[email protected]
or
Investor Relations
Mary T. Conway, 617-768-2628
Investor Relations
[email protected]

Source: Ironwood Pharmaceuticals, Inc.

You May Also Be Interested In

• Monster Energy's Max Alran Takes First Place in Downhill Mountain Bike Race at the 2026 WHOOP UCI Mountain Bike World Series Les Gets
• Solana Unchained Emerges as a Closely Watched Solana Presale Following Product Ecosystem Reveal
• Dogecoin and Floki Got Away While You Waited: APEING Could Be the Next 100x Meme Coin With Over 12,000+ Whitelist Members